CTRC-AACR San Antonio Breast Cancer Symposium Continues To Expand

Main Category: Breast Cancer
Also Included In: Conferences;  Clinical Trials / Drug Trials
Article Date: 04 Dec 2009 - 3:00 PDT

email to a friend   printer friendly   opinions  

Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal of eradicating breast cancer.

This year, more than 8,500 scientists and other professionals will gather at the Henry B. Gonzales Convention Center in San Antonio from Dec. 9-13, 2009. The symposium is a partnership between the American Association for Cancer Research, the University of Texas Health Science Center and Baylor College of Medicine.

Last year, more than 8,000 people attended from 92 countries; 46 percent of the participants were medical doctors and 9 percent were basic research scientists. Last year was the first year the AACR partnered with the symposium in an effort to help increase the presence of basic science. As a result, the meeting began one day earlier than in past years and held standing room only scientific sessions.

"The San Antonio Breast Cancer Symposium is arguably the best cancer research meeting in the world, and with the addition of high quality science, credibility and outreach efforts from the American Association for Cancer Research, this collaboration continues to garner further scientific prominence," said C. Kent Osborne, M.D., director of the Dan L. Duncan Center and the Lester and Sue Smith Breast Center at Baylor College of Medicine and president of the symposium.

This year, in addition to the main program, the CTRC-AACR-SABCS press office will host four press conferences for the media highlighting important news from the meeting and a separate media Q&A on December 12 at 10:00 a.m. CT with Dennis Slamon, M.D., Ph.D. on the long-term survival, disease free survival and cardiac toxicity results from his latest research with Herceptin.

The following is a schedule of the press briefings. A press kit containing releases, abstracts and dial-in information for each briefing is included as a part of this wire:

-- Bisphosphonates: 12:30 p.m. CT, Thursday, Dec. 10

-- Drugs in the Pipeline: 8:00 a.m. CT, Friday, Dec. 11

-- New Treatment Paradigms: 12:30 p.m. CT, Friday, Dec. 11

-- Patient Management and Prognosis: 8:00 a.m. CT, Saturday, Dec. 12

-- Media Q&A with Dennis Slamon, M.D., Ph.D, 10:00 a.m. CT, Saturday, Dec. 12

Beyond the press conferences, the press office has selected additional abstracts that may be of interest to the media. Press releases on those abstracts will also be included as a part of this wire.

AACR will be conducting interviews with researchers throughout the symposium. Recordings of these events and interviews will be posted to AACR Scientific Podcast feed.

The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 32nd annual symposium is expected to draw more than 8,500 participants from more than 90 countries.

Source: American Association for Cancer Research

• Additional
• References
• Citations